Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$46.36
$0.54(1.32%)
At close: 4:00 PM EDT
$46.36
$0.54(1.32%)
Day’s Range― - ―
52-Week Range$15.86 - $50.81
Previous CloseN/A
Volume333.78K
Average Volume (3M)678.69K
Market Cap
$2.02B
Enterprise Value$1.94B
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 05, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume757,682
30 Day Avg. Volume678,686
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue10.28
Enterprise Value/Gross Profit11.32
Enterprise Value/Ebitda-27.45
Forecast
1Y Price Target
$60.20Price Target Upside29.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$322.20M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial AdoptionZUSDURI is showing strong early commercial traction, with growing revenue, hospital and community adoption, and increasing repeat utilization. Expanding prescriber engagement can build a durable revenue base and improve the company’s ability to leverage its uro-oncology platform over the next several quarters.
Durable Clinical ProfileLong-term disease-control data strengthen the clinical foundation of UroGen’s product and pipeline strategy. Durable responses without maintenance therapy may support physician confidence, patient value, and differentiation as the company expands its presence in urothelial cancer treatment.
Strong Product EconomicsHigh and consistent gross margins indicate attractive product-level economics, while substantial revenue growth shows expanding commercial scale. If operating costs become better matched to revenue, this combination could provide meaningful operating leverage and support eventual profitability.
Bears Say
Negative Equity And Rising DebtNegative shareholder equity and materially higher debt leave UroGen with limited balance-sheet flexibility while losses continue. This capital structure increases financial risk, can constrain investment choices, and makes rebuilding equity through sustained profitability especially important.
Persistent Cash BurnSustained operating and free-cash-flow deficits show that the business is still consuming substantial capital rather than self-funding operations. Continued burn can increase dependence on external financing and reduce the company’s ability to absorb execution setbacks or fund pipeline expansion.
High Costs And Launch UncertaintyUroGen is increasing spending on commercialization and development before the ZUSDURI launch has an established full-year revenue outlook. The combination of elevated costs and limited demand visibility could delay profitability and make future earnings more dependent on successful execution.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $15.86 and its highest was $50.81 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $2.02B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.1.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 16.308%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.20 (29.85% Upside)
$60.20 (29.85% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 86%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$60.20
▲(29.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.77% Insiders
5.16% Mutual Funds
43.99% Other Institutional Investors
41.55% Public Companies and
Individual Investors